ATE385799T1 - Zusammensetzung einer natriumkanal-blockierenden verbindung - Google Patents

Zusammensetzung einer natriumkanal-blockierenden verbindung

Info

Publication number
ATE385799T1
ATE385799T1 AT01997312T AT01997312T ATE385799T1 AT E385799 T1 ATE385799 T1 AT E385799T1 AT 01997312 T AT01997312 T AT 01997312T AT 01997312 T AT01997312 T AT 01997312T AT E385799 T1 ATE385799 T1 AT E385799T1
Authority
AT
Austria
Prior art keywords
sodium channel
composition
blocking compound
channel blocking
region
Prior art date
Application number
AT01997312T
Other languages
English (en)
Inventor
Yuhong Kang
Frank Shum
Original Assignee
Nanning Maple Leaf Pharmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Maple Leaf Pharmaceuti filed Critical Nanning Maple Leaf Pharmaceuti
Application granted granted Critical
Publication of ATE385799T1 publication Critical patent/ATE385799T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01997312T 2000-11-22 2001-11-19 Zusammensetzung einer natriumkanal-blockierenden verbindung ATE385799T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001326724A CN1236773C (zh) 2000-11-22 2000-11-22 用于镇痛、麻醉或治疗药物依赖性的制剂

Publications (1)

Publication Number Publication Date
ATE385799T1 true ATE385799T1 (de) 2008-03-15

Family

ID=4595311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01997312T ATE385799T1 (de) 2000-11-22 2001-11-19 Zusammensetzung einer natriumkanal-blockierenden verbindung

Country Status (8)

Country Link
US (1) US6559154B2 (de)
EP (2) EP1930027A3 (de)
JP (1) JP2004513186A (de)
CN (1) CN1236773C (de)
AT (1) ATE385799T1 (de)
AU (1) AU2002221491A1 (de)
DE (1) DE60132798T2 (de)
WO (1) WO2002041915A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US20030100574A1 (en) 2001-11-15 2003-05-29 Wilson Nestor Antonio Lagos Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
CA2607206C (en) * 2004-05-07 2016-06-14 Phytotox Limited Transdermal administration of phycotoxins
EP1824488B1 (de) * 2004-05-07 2017-08-09 Algenis SpA Phycotoxine und verwendungen damit
US20090143415A1 (en) * 2004-09-21 2009-06-04 Wex Pharmaceuticals, Inc. Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain
JP2008513528A (ja) * 2004-09-22 2008-05-01 ウェックス ファーマシューティカルズ インコーポレイテッド 末梢神経由来の神経障害性疼痛の治療用テトロドトキシンおよびその誘導体
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
EP1928452A4 (de) * 2005-08-25 2010-09-01 Wex Medical Ltd Verwendung von natriumkanalblockern zur behanldung von viszeralen schmerzen oder schmerzen durch krebsbehandlung
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
CN101563079B (zh) * 2006-03-27 2012-12-05 威克斯药业有限公司 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
HUE042711T2 (hu) 2013-03-15 2019-07-29 Childrens Medical Ct Corp Neosaxitoxin kombinációs készítmények meghosszabbított helyi érzéstelenítésre

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US3898339A (en) * 1973-08-14 1975-08-05 Astra Pharma Prod Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
EP0750909B1 (de) * 1994-03-17 2002-12-11 Nanning Maple Leaf Pharmaceutical Co., Ltd. Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit
CN1081034C (zh) * 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1240702C (zh) 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法

Also Published As

Publication number Publication date
DE60132798D1 (de) 2008-03-27
WO2002041915A1 (en) 2002-05-30
CN1353990A (zh) 2002-06-19
US6559154B2 (en) 2003-05-06
EP1335747B1 (de) 2008-02-13
EP1335747A4 (de) 2005-10-12
AU2002221491A1 (en) 2002-06-03
US20020119987A1 (en) 2002-08-29
JP2004513186A (ja) 2004-04-30
EP1930027A3 (de) 2008-06-18
CN1236773C (zh) 2006-01-18
DE60132798T2 (de) 2009-02-12
EP1930027A2 (de) 2008-06-11
EP1335747A1 (de) 2003-08-20

Similar Documents

Publication Publication Date Title
DE60132798D1 (de) Zusammensetzung einer natriumkanal-blockierenden verbindung
PT1109812E (pt) Pirrolobenzodiazepinas
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
DK1301436T3 (da) Fremgangsmåder til syntese af et oxidationsmiddel samt dets anvendelse
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
PL360092A1 (en) Structures and compositions increasing the stability of peroxide actives
NO20034660D0 (no) Spiropyrazolforbindelser
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
HK1029754A1 (en) Formulations for protection of peg-interferon alpha conjugates.
DE60112960D1 (de) Kondensierte pyridoindolderivate
SE9801494D0 (sv) Novel use
BG106316A (en) Ambroxol-containing lozenge
HUP0202592A2 (hu) Lazofoxifen transzdermális adagolása
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
BR0114065A (pt) Triazolo-epotilonas
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
GT199900037A (es) Nuevas composiciones herbicidas.
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
DK1052995T3 (da) Farmaceutisk præparat til nasal indgivelse af thiocolchicosid
ATE249204T1 (de) Spray, enthaltend ubichinon qn
BR8002856U (pt) Televisão relógio
YU30198A (sh) Prečišćavanje propilen oksida

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties